
Bechara G Mfarrej

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6396667/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. Journal of Experimental Medicine, 2008, 205, 3133-3144.	4.2	277
2	The Link between the PDL1 Costimulatory Pathway and Th17 in Fetomaternal Tolerance. Journal of Immunology, 2011, 187, 4530-4541.	0.4	145
3	Deleterious Effect of CTLA4-Ig on a Treg-Dependent Transplant Model. American Journal of Transplantation, 2012, 12, 846-855.	2.6	123
4	IL-10 Receptor Signaling Is Essential for TR1 Cell Function In Vivo. Journal of Immunology, 2017, 198, 1130-1141.	0.4	108
5	Critical Role of Proinflammatory Cytokine IL-6 in Allograft Rejection and Tolerance. American Journal of Transplantation, 2012, 12, 90-101.	2.6	93
6	TIM-3 Regulates Innate Immune Cells To Induce Fetomaternal Tolerance. Journal of Immunology, 2013, 190, 88-96.	0.4	92
7	Polylactideâ€cyclosporin A nanoparticles for targeted immunosuppression. FASEB Journal, 2010, 24, 3927-3938.	0.2	78
8	Renin–angiotensin-system gene polymorphisms and depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1113-1118.	2.5	73
9	TIM-3: A Novel Regulatory Molecule of Alloimmune Activation. Journal of Immunology, 2010, 185, 5806-5819.	0.4	69
10	Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression. Scientific Reports, 2017, 7, 6897.	1.6	53
11	Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood, 2011, 117, 1176-1183.	0.6	43
12	Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression. Journal of Translational Medicine, 2017, 15, 40.	1.8	39
13	Dual-Kidney Transplants as an Alternative for Very Marginal Donors: Long-Term Follow-Up in 63 Patients. Transplantation, 2010, 90, 1125-1130.	0.5	34
14	The Novel Role of SERPINB9 in Cytotoxic Protection of Human Mesenchymal Stem Cells. Journal of Immunology, 2011, 187, 2252-2260.	0.4	32
15	Derivation and Validation of a Cytokine-Based Assay to Screen for Acute Rejection in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1018-1025.	2.2	32
16	Monocyte-Secreted Inflammatory Cytokines Are Associated With Transplant Glomerulopathy in Renal Allograft Recipients. Transplantation, 2011, 91, 552-559.	0.5	30
17	Immune Profile of Pediatric Renal Transplant Recipients following Alemtuzumab Induction. Journal of the American Society of Nephrology: JASN, 2012, 23, 174-182.	3.0	30
18	B7h (ICOS-L) Maintains Tolerance at the Fetomaternal Interface. American Journal of Pathology, 2013, 182–2204-2213	1.9	30

2

BECHARA G MFARREJ

#	Article	IF	CITATIONS
19	Manufacturing Natural Killer Cells as Medicinal Products. Frontiers in Immunology, 2016, 7, 504.	2.2	30
20	IL-21 Is an Antitolerogenic Cytokine of the Late-Phase Alloimmune Response. Diabetes, 2011, 60, 3223-3234.	0.3	26
21	Glomerular Inflammation Correlates With Endothelial Injury and With IL-6 and IL-1β Secretion in the Peripheral Blood. Transplantation, 2014, 97, 1034-1042.	0.5	24
22	Generation of Donor-specific T Regulatory Type 1 Cells From Patients on Dialysis for Cell Therapy After Kidney Transplantation. Transplantation, 2015, 99, 1582-1589.	0.5	24
23	Sickle cell disease: the Lebanese experience. International Journal of Laboratory Hematology, 2007, 29, 399-408.	0.7	23
24	Improved Function of Circulating Angiogenic Cells Is Evident in Type 1 Diabetic Islet-Transplanted Patients. American Journal of Transplantation, 2010, 10, 2690-2700.	2.6	22
25	From clinical proof-of-concept to commercialization of CAR T cells. Drug Discovery Today, 2018, 23, 758-762.	3.2	17
26	Green Tea Epigallo-Catechin-Galleate Ameliorates the Development of Obliterative Airway Disease. Experimental Lung Research, 2011, 37, 435-444.	0.5	13
27	Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts. Cytotherapy, 2017, 19, 1501-1508.	0.3	13
28	Prolonged, Low-Dose Anti-Thymocyte Globulin, Combined with CTLA4-Ig, Promotes Engraftment in a Stringent Transplant Model. PLoS ONE, 2013, 8, e53797.	1.1	12
29	Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor. Cancers, 2021, 13, 2673.	1.7	12
30	Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection. Frontiers in Immunology, 2017, 8, 811.	2.2	10
31	Driving Medical Innovation Through Interdisciplinarity: Unique Opportunities and Challenges. Frontiers in Medicine, 2019, 6, 35.	1.2	10
32	Effect of biologic agents on regulatory T cells. Transplantation Reviews, 2011, 25, 110-116.	1.2	9
33	Decompression of Inflammatory Edema along with Endothelial Cell Therapy Expedites Regeneration after Renal Ischemia-Reperfusion Injury. Cell Transplantation, 2013, 22, 2091-2103.	1.2	9
34	Key role of macrophages in tolerance induction via T regulatory type 1 (Tr1) cells. Clinical and Experimental Immunology, 2020, 201, 222-230.	1.1	9
35	Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular products. Cytotherapy, 2021, 23, 77-87.	0.3	8
36	Related versus unrelated allogeneic HPC graft cryopreservation: a single-center experience in the context of the global COVID-19 pandemic. Bone Marrow Transplantation, 2021, 56, 2013-2015.	1.3	7

BECHARA G MFARREJ

#	Article	IF	CITATIONS
37	Determination of optimal incubation time for the production of acute phase cytokines ex vivo by peripheral blood mononuclear cells from renal transplant recipients. Journal of Immunological Methods, 2011, 366, 119-122.	0.6	4
38	Developing translational medicine professionals: the Marie SkÅ,odowska-Curie action model. Journal of Translational Medicine, 2016, 14, 329.	1.8	4
39	A matchedâ€pair analysis reveals marginally reduced CD34+ cell mobilization on second occasion in 27 related donors who underwent peripheral blood stem cell collection twice at the same institution. Transfusion, 2019, 59, 3442-3447.	0.8	4
40	Anti-CD3 mAb treatment cures PDL1â^'/â^'.NOD mice of diabetes but precipitates fatal myocarditis. Clinical Immunology, 2011, 140, 47-53.	1.4	2
41	Relief of the Renal Pressure after Ischemia-Reperfusion Injury Reduces the Inflammatory Response Within Ischemic Kidneys. Transplantation, 2012, 94, 261.	0.5	0
42	The "Unusual Suspects―in Allograft Rejection: Will T Regulatory Cell Therapy Arrest Them?. Current Transplantation Reports, 2016, 3, 221-226.	0.9	0
43	Pre-clinical validation of Lovo for post-thaw DMSO depletion from cryopreserved stem cells. Cytotherapy, 2017, 19, S50.	0.3	0
44	Feasibility and safety of allogeneic ex vivo activated-NK cell infusion after matched related hematopoietic stem cell transplantation: Preliminary results of a prospective phase I trial. Cytotherapy, 2017, 19, S16.	0.3	0
45	Mobilization regimen, including Plerixafor, does not impact CD34 recovery after automated post-thaw processing. Cytotherapy, 2020, 22, S147.	0.3	0
46	The Path To Commercialize CAR-T Cell Products. , 2018, , .		0
47	Validation of a flow cytometry-based method for quantitative viable lymphocyte- immunophenotyping in fresh and cryopreserved hematopoietic cellular products. Cytotherapy, 2020, 22, S155.	0.3	0